'Inequity in access to #treatments is a violation of #humanrights . #ASCERTAIN is crucial to eliminate these inequities,' says Peter Kapitein.
Meet Peter, founder of Inspire2Live, a global patient advocacy organization🌍 #AdvisoryBoard access2meds.eu/advisory-board/

💌 Stay in the loop with the latest advancements in healthcare accessibility and affordability. Subscribe to the #ASCERTAIN newsletter and be the first to know about innovative solutions, research insights, and more! Subscribe now: access2meds.eu/about-ascertai…

Welcome Yannis Natsis to our Advisory Board! 🌟 ' #ASCERTAIN addresses the high #prices of new #treatments , testing European welfare states. Now or never to reflect and prepare,' says Yannis. Meet our #AdvisoryBoard : lnkd.in/dUU9hVWC 🌍💙 #HealthcareInnovation

EU funded project ASCERTAIN , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members
access2meds.eu/about-ascertai…

Kicking off the new year🚀➡ASCERTAIN's third consortium meeting on January 16th and 17th📸Consortium members, stakeholders and Advisory Board representatives worked together to shape our path for the year. #healthtech #accessibility

AIM's Fair Pricing Model is the basis for the ASCERTAIN project and will be taken further.

AIM is participating in the Consortium Meeting ASCERTAIN and is a proud partner of that project.

Nous avons interviewé .Jean-Pascal Labille de .Solidaris Wallonie sur le juste prix des #médicaments 💊

'Depuis 2015, les dépenses de médicaments sont devenues incontrôlables'

👉L'interview complète: bit.ly/46KuNWP

Join us at the 6th European CAR T-cell Meeting in Valencia!
📅 16 February 2024, 09:40 – 09:45
➡ Session PS04B Translational II – Focus on European Project & Networks
#ASCERTAIN
European Hematology Association

'Without a better knowledge on R&D costs, we will never be able to negotiate a 'fair' price for all parties' says Anne Hendrickx. Join her at the #A2MForum this week!

📅 8 December 2023
📍 Brussels
EPHA

Your input is crucial!

Together with ASCERTAIN, EHA is working to improve equitable access to drugs through pricing models and value assessment models addressing the needs of patients, doctors, and payers.

Fill in the survey: eha.fyi/ascertain_surv…

What's a fair price for health technologies? Poster with first findings from a review of fair pricing definitions at #ISPOR
ASCERTAIN Gesundheit Österreich

Let's take actions to make innovative therapies accessible to all. 🌐🩺 #PrecisionMedicine #Cancer Research #Oncology #Cancer

🔬📚'Access and Quality of Biomarker Testing for Precision Oncology in Europe'. Explore #CancerPrecision in Europe. Key findings: access, funding challenges, NGS use, & quality assurance. Action needed for equal access to innovative therapies🔗cutt.ly/UwEiA4S3 #Healthcare

'Als kankerpatiënt ben je afhankelijk van de arts die bepaalde opties heeft om jou te behandelen. Die markt is gewoon heel anders, het is beslist geen vrije markt,' volgens hoogleraar Carin Uyl-de Groot in IKNL eur.nl/eshpm/nieuws/v…
Erasmus University #drugpricing ASCERTAIN

We are proud to be part of the ASCERTAIN project!
The pharmacoeconomics team of Gesundheit Österreich takes the lead in developing new approaches for pricing innovative technologies to improve patient access and stimulate entrepreneurship.
Learn more 🎓access2meds.eu

#ReadingTip 📊🔬The European Medicines Agency (EMA) supports pharmaceutical companies through Business Pipeline Meetings (BPMs). An analysis of BPMs in oncology from 2018 to 2022 revealed interesting findings #PharmaceuticalInnovation #OncologyResearch
🔗ascpt.onlinelibrary.wiley.com/doi/full/10.10…

#ISPOREurope2023 sessions🌎
➡️Unveiling the EU-HTA Regulation: A Deep Dive Into the Joint Clinical Assessment
➡️Horizon Europe Project: Supporting a Sustainable & Transparent Legal EU HTA Framework, Accessibility of Innovative Technologies & Health Equity🔗cutt.ly/ewQEcEIo

Discover our innovative framework, built on core values like healthcare access, equity, & sustainability🔄It's an iterative process designed to adapt to evolving healthcare landscapes🔗 Reconciling EU regulations with our vision for accessible healthcare👉access2meds.eu/ascertain-news…